# Janssen Korea, Ltd., Korea clinical trials: 79 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 79 trials with Janssen Korea, Ltd., Korea as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen Korea, Ltd., Korea: 79 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-korea-ltd-korea

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 79
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 79, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07890285 | A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea | Janssen Korea, Ltd., Korea | Observational | Not yet recruiting | Pulmonary Arterial Hypertension | 333 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890285) |
| July 30, 2026 | NCT07735793 | A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea | Janssen Korea, Ltd., Korea | Observational | Recruiting | Urinary Bladder Neoplasms | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735793) |
| April 9, 2026 | NCT07520747 | A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea | Janssen Korea, Ltd., Korea | Observational | Active not recruiting | Inflammatory Bowel Diseases | 8,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07520747) |
| July 8, 2025 | NCT07053345 | A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression | Janssen Korea, Ltd., Korea | Phase 4 | Completed | Depressive Disorder, Treatment-Resistant | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053345) |
| April 21, 2021 | NCT04852692 | A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants | Janssen Korea, Ltd., Korea | Observational | Terminated | Chronic Graft vs Host Disease | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04852692) |
| January 18, 2020 | NCT04230252 | A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in... | Janssen Korea, Ltd., Korea | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04230252) |
| January 2, 2020 | NCT04214691 | A Study of Newly Formulated Tylenol Tablet (Acetaminophen) and Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy... | Janssen Korea, Ltd., Korea | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04214691) |
| May 8, 2019 | NCT03942120 | Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab) | Janssen Korea, Ltd., Korea | Observational | Completed | Crohn Disease | 685 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03942120) |
| July 22, 2015 | NCT02505568 | A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease | Janssen Korea, Ltd., Korea | Phase 3 | Completed | Behcet Disease | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02505568) |
| June 17, 2015 | NCT02474563 | Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma | Janssen Korea, Ltd., Korea | Observational | Completed | Multiple Myeloma | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02474563) |
| September 1, 2014 | NCT02229344 | Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea | Janssen Korea, Ltd., Korea | Observational | Completed | Colitis, Ulcerative | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02229344) |
| December 16, 2013 | NCT02012049 | Bioequivalence Test for Risperdal 2mg of Janssen Korea | Janssen Korea, Ltd., Korea | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02012049) |
| July 18, 2013 | NCT01902537 | An Observational Study to Evaluate the Quality of Life in Korean Female Participants With Chronic Constipation | Janssen Korea, Ltd., Korea | Observational | Completed | Constipation | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01902537) |
| July 18, 2013 | NCT01902524 | Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain | Janssen Korea, Ltd., Korea | Phase 4 | Completed | Chronic Pain | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01902524) |
| April 11, 2013 | NCT01829828 | The Effectiveness of a Patient Self-reported Pain Scoring Tool and a Satisfaction Survey on Cancer Pain Management | Janssen Korea, Ltd., Korea | Observational | Completed | Pain | 587 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01829828) |
| March 28, 2013 | NCT01819818 | A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients | Janssen Korea, Ltd., Korea | Observational | Completed | Schizophrenia | 3,267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01819818) |
| March 28, 2013 | NCT01819805 | A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol... | Janssen Korea, Ltd., Korea | Observational | Completed | Chronic Pain | 1,065 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01819805) |
| March 22, 2013 | NCT01816503 | Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study | Janssen Korea, Ltd., Korea | Observational | Completed | Pain | 636 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01816503) |
| March 20, 2013 | NCT01814878 | A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release... | Janssen Korea, Ltd., Korea | Phase 3 | Completed | Pain, Postoperative | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01814878) |
| March 1, 2013 | NCT01802359 | A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction | Janssen Korea, Ltd., Korea | Observational | Terminated | Erectile Dysfunction | 379 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01802359) |
| January 29, 2013 | NCT01778075 | A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under... | Janssen Korea, Ltd., Korea | Phase 1 | Completed | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01778075) |
| December 5, 2012 | NCT01741844 | A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence | Janssen Korea, Ltd., Korea | Observational | Completed | Acquired Immune Deficiency Syndrome | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01741844) |
| December 5, 2012 | NCT01741831 | A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista | Janssen Korea, Ltd., Korea | Observational | Completed | Acquired Immune Deficiency Syndrome | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01741831) |
| November 27, 2012 | NCT01734395 | A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine... | Janssen Korea, Ltd., Korea | Observational | Completed | Alzheimer's Disease | 1,882 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01734395) |
| October 15, 2012 | NCT01706562 | A Study of Empirical Antifungal Therapy With Itraconazole | Janssen Korea, Ltd., Korea | Observational | Completed | Neutropenia | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01706562) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 3 | 3 |
| Phase 4 | 30 |
| Observational | 42 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 73 |
| Terminated | 3 |
| Active not recruiting | 1 |
| Recruiting | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 11 |
| Pain | 10 |
| Cancer Pain | 6 |
| Multiple Myeloma | 6 |
| Chronic Pain | 5 |
| Epilepsy | 3 |
| Osteoarthritis | 3 |
| Alzheimer Disease | 3 |
| Attention Deficit Disorder with Hyperactivity | 3 |
| Arthritis, Rheumatoid | 3 |
| Hematologic Neoplasms | 3 |
| Neutropenia | 3 |
| Mental Disorders | 3 |
| Crohn Disease | 2 |
| Spondylitis, Ankylosing | 2 |
| Seizures | 2 |
| Gastroesophageal Reflux | 2 |
| Myelodysplastic Syndromes | 2 |
| Low Back Pain | 2 |
| Fever | 2 |
| Acquired Immunodeficiency Syndrome | 2 |
| Headache | 1 |
| Osteoarthritis, Hip | 1 |
| Osteoarthritis, Knee | 1 |
| Arthritis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Hospitals in the United States](https://specstream.ai/data/businesses/hospitals/united-states)
- [Certification bodies in the United States](https://specstream.ai/data/businesses/certification-bodies/united-states)
- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
- [Family practice clinics in the United States](https://specstream.ai/data/businesses/family-practice-clinics/united-states)
